Compositions and methods for diagnosis and treatment of neurodegenerative diseases
AssigneeEpitracker, Inc.
InventorStephanie Venn-Watson
Life of this patent
Estimating the term…
Abstract
Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neurodegenerative diseases are provided, including compositions and methods for detecting and treating conditions that contribute to neurodegenerative diseases, including peripheral and central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition and hyperglycemia.
Claims20
A method of treatment or prophylaxis of a neurodegenerative disease selected from the group consisting of Alzheimer's disease, dementias, Parkinson's disease, prion disease, motor neuron diseases, Huntington's disease, spinocerebellar ataxia, and spinal muscular atrophy;
- for treatment of one or more conditions that are contributors to neurodegenerative disease, wherein the one or more conditions are selected from the group consisting of peripheral, inflammation, central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition, hyperglycemia, Th1-type inflammation, Th2-type inflammation, T-cell dependent B cell proliferation, allergy, asthma, atherosclerosis, autoimmunity, chronic inflammation, chronic obstructive pulmonary disease (COPD), Crohn's disease, cutaneous responses to tissue damage, fibrosis, hematological oncology, a metabolic disease, organ transplantation, psoriasis, pulmonary fibrosis, a pulmonary response to respiratory infection, restenosis, rheumatoid arthritis, sarcoidosis, stromal biology in tumors, systemic lupus erythematosus (SLE), ulcerative colitis, and vascular inflammation;
- or for treatment of a neurodegenerative disease that is driven or exacerbated by one or more factors selected from the group consisting of alpha smooth muscle actin (αSMA), CD38, CD40, collagen I, collagen III, e-selectin, fibroblast proliferation, human leukocyte antigen-DR isotype (HLA-DR), immunoglobulin G, interferon gamma-induced protein 10 (IP-10/CXCL10), interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), interleukin (IL)-6, IL-8 (CXCL8), IL-17A, macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase (MMP)-1, MMP-9, monocyte chemoattractant protein 1 (MCP-1), P selectin, plasminogen activation inhibitor 1 (PAI-1), prostaglandin E2 (PGE2), T cell proliferation, thrombomodulin, tissue factor, TIMP-1, tumor necrosis factor alpha (TNFα), vascular cell adhesion molecule (VCAM-1), and vascular endothelial growth factor 2 (VEGFR2), the method comprising:
- administering to a patient in need thereof, an effective amount of one or more small molecule biochemicals, or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof.
A pharmaceutical composition for treatment or prophylaxis of a neurodegenerative disease selected from the group consisting of Alzheimer's disease, dementias, Parkinson's disease, prion disease, motor neuron diseases, Huntington's disease, spinocerebellar ataxia, and spinal muscular atrophy;
- for treatment of one or more conditions that are contributors to neurodegenerative disease, wherein the one or more conditions are selected from the group consisting of peripheral and central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition, hyperglycemia, Th1-type inflammation, Th2-type inflammation, T-cell dependent B cell proliferation, allergy, asthma, atherosclerosis, autoimmunity, chronic inflammation, chronic obstructive pulmonary disease (COPD), Crohn's disease, cutaneous responses to tissue damage, fibrosis, hematological oncology, metabolic diseases, organ transplantation, psoriasis, pulmonary fibrosis, pulmonary responses to respiratory infections, restenosis, rheumatoid arthritis, sarcoidosis, stromal biology in tumors, systemic lupus erythematosus (SLE), ulcerative colitis, and vascular inflammation;
- or for treatment of a neurodegenerative disease that is driven or exacerbated by one or more factors selected from the group consisting of alpha smooth muscle actin (αSMA), CD38, CD40, collagen I, collagen III, e-selectin, fibroblast proliferation, human leukocyte antigen-DR isotype (HLA-DR), immunoglobulin G, interferon gamma-induced protein 10 (IP-10/CXCL10), interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), interleukin (IL)-6, IL-8 (CXCL8), IL-17A, macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase (MMP)-1, MMP-9, monocyte chemoattractant protein 1 (MCP-1), P selectin, plasminogen activation inhibitor 1 (PAI-1), prostaglandin E2 (PGE2), T cell proliferation, thrombomodulin, tissue factor, TIMP-1, tumor necrosis factor alpha (TNFα), vascular cell adhesion molecule (VCAM-1), and vascular endothelial growth factor 2 (VEGFR2), the pharmaceutical composition comprising:
- one or more small molecule biochemicals, or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.